tbuckley/cabot-search huggingface dataset:
The 1st Euro-Mediterranean Workshop: Natural Products in Health and Diseases: Cairo, Egypt, March 2, 2015
Authors: Kamal D. Moudgil, Ashraf A. Khalil
Journal: Asian Journal of Pharmaceutical Sciences (2016)

Natural plant products have been used for centuries for health maintenance and treatment of a variety of diseases in various traditional systems of medicine in Egypt and other African countries, India, China, and other countries around the world. Over the past several decades, the popularity of herbal and other natural products has gradually increased in many western countries. Despite the increasing popularity of natural products, both the public and the professionals are skeptical about the use of these products. Reasons for this skepticism include, but are not limited to, the lack of proper documentation about the source and formulations used; standardization of the composition, batch-to-batch consistency, documented safety of herbal products; and information about the mechanisms of action of these products. The 1st Euro-Mediterranean Workshop: Natural Products in Health and Diseases was organized by the Euro-Mediterranean Association of Life Sciences (EMALS) and various other local organizations to review and discuss the above-mentioned strengths and limitations of the use of natural products. The aim of this workshop was to share best practices and expertise about natural products, and to identify opportunities for collaboration among researchers, health professionals, and business personnel in a productive atmosphere.
Quality of life and LhRH agonist therapy among prostate cancer patients who experience PSA failure
Authors: K. F. Kline, O. Sartor, N. A. Dandade, N. J. Nonzee, B. D. Vicuna, C. L. Bennett
Journal: Journal of Clinical Oncology (2007)

9093 Background: Growing numbers of prostate cancer patients survive for extended periods of time after initial diagnosis and treatment. Many experience a biochemical relapse (“PSA failure”) some time after prostatectomy or pelvic radiation. LhRH agonist therapy can reduce PSA levels, but its impact on survival time and quality of life (QOL) is unclear. We evaluated these concerns among Veterans who experienced PSA Failure. Methods: Eligibility criteria included: receipt of primary therapy for prostate cancer followed by a PSA nadir and subsequent PSA rise to at least 0.2 ng/ml. Data sources include patients (interviewer administered survey instruments on health-related QOL at baseline, 3 and 12 months) and medical records (clinical and laboratory findings). Results: 69 patients from the Jesse Brown VA Medical Center in Chicago have enrolled in the study to date. At their baseline interviews, 30 patients (43.5%) were receiving LhRH agonists (46.1% of 39 African-American patients and 48.0% of 25 White patients). LhRH agonist patients reported worse health-related QOL in domains relevant to prostate cancer than watchful waiting (WW) patients ( Table ), including increased frequency of urination, difficulty controlling urination, greater erectile dysfunction, and more limits on sexual activity. LhRH agonist and WW patients reported similar levels of sexual satisfaction. Conclusion: Of the PSA failure patients studied in this sample, those receiving LhRH agonist therapy experience more problems with urinary and sexual function than those who opted for WW. Longitudinal study will provide information about whether the LhRH therapy causes these side effects, or whether symptomatic patients are more likely to choose LhRH therapy than those with few prostate cancer symptoms. [Table: see text] No significant financial relationships to disclose.
Inflammation Induces Hematopoietic Stem Cell/Progenitor Migration and Recruitment To Lymph Nodes In Mice and Humans
Authors: Juana Serrano, Josefina Serrano, Kyung-Hee Chang, Yami Rangel, Beatriz sanchez-Espiridion, Ashley Ficker, Jose A. Cancelas, Joaquin sanchez-Garcia
Journal: Blood (2013)
Response to Letter Regarding Article, “Endovascular Versus External Targeted Temperature Management for Patients With Out-of-Hospital Cardiac Arrest: A Randomized, Controlled Study”
Authors: Nicolas Deye, Alain Cariou, Patrick Girardie, Nicolas Pichon, Bruno Megarbane, Philippe Midez, Jean-Marie Tonnelier, Thierry Boulain, Hervé Outin, Arnaud Delahaye, Aurélie Cravoisy, Alain Mercat, Pascal Blanc, Charles Santré, Hervé Quintard, François Brivet, Julien Charpentier, Delphine Garrigue, Bruno Francois, Jean-Pierre Quenot, François Vincent, Pierre-Yves Gueugniaud, Jean-Paul Mira, Pierre Carli, Eric Vicaut, Frédéric J. Baud
Journal: Circulation (2016)
Non-Hodgkin’s lymphoma of the thyroid—A review of 16 cases
Authors: L. V. Soman, G. Narayanan, M. Hussain, J. Madhavan
Journal: Journal of Clinical Oncology (2008)

19539 Background: Non Hodgkin’s lymphoma(NHL) of the thyroid is rare. We present our experience with this disease. Aim: To study the presentation, treatment and survival of patients with NHL of the thyroid gland. Methods: Sixteen patients with NHL of the thyroid was seen and treated by us at Regional Cancer Centre, Trivandrum, India during the period 2000 - 2005. The clinical and treatment details of these patients were analysed and survival data collected Results: Among 16 cases, there were 9 males and 7 females. The median age at presentation was 63 years (range 31–75 yrs). The predominant symptoms were swelling of the neck (14), stridor/ dyspnoea (8), and hoarseness (3). The median duration of symptom was 4 months. Lymph nodes of the neck was palpable in 3, and 1 had B symptoms. Bone marrow was positive in 2 cases. The Ann Arbor stage was I in 9, II in 3, III in 2, and IV in 2. The histopathology subtypes were Diffuse Large B cell in 6, MALT in 2, and one each of marginal zone, follicular large cell and the subtype was not specified in 4 cases. One patient each had NHL in association with Hashimoto’s thyroiditis and papillary carcinoma of thyroid. CD20 was positive in 10 cases. Fourteen patients received treatment, 5 had surgery and chemotherapy, 4 surgery alone, 2 had chemotherapy along with radiation, 2 had chemotherapy alone and 1 radiation alone. Chemotherapy consisted of combinations of cyclophosphamide, doxorubicin or mitoxantrone, vincristne and prednisolone. Seven patients underwent total thyroidectomy, and 2 subtotal thyroidectomy. Radiation dose ranged from 35–40 Gy. Median survival was 24 months. Conclusions: NHL thyroid is a disease of the elderly, predominantly of diffuse large B cell subtype and needs multimodality management. No significant financial relationships to disclose.
Abstract P431: Neck Circumference as a New Clinical Predictor of Incident Diabetes Mellitus: Results from 9-Year Follow-Up of the Jackson Heart Study
Authors: Jiankang Liu, Sean Coady, DeMarc A Hickson, Herman A Taylor, Caroline S Fox
Journal: Circulation (2013)

Background-Upper body subcutaneous fat, as estimated by neck circumference (NC), has been demonstrated to confer cardiometabolic risk above and beyond visceral abdominal fat. However, it is unclear...
A combination phase I study of amrubicin and irinotecan (CPT-11) in patients with lung cancer
Authors: T. Kurata, H. Kaneda, K. Tamura, T. Satoh, T. Nogami, H. Uejima, K. Nakagawa, M. Fukuoka
Journal: Journal of Clinical Oncology (2005)

7332 Background: A synergistic effect between topo I and topo II inhibitors in vivo has been reported by several investigators. Amrubicin is a synthetic 9-amino-anthracycline derivative that has demonstrated excellent activities for both extensive small-cell lung cancer and advanced non-small-cell lung cancer as a topo II inhibitor. The aim of this study were to determine the maximum tolerated dose (MTD) of amrubicin in combination with the topo I inhibitor, CPT-11, and to describe the toxicity profile, the pharmacokinetic profile, and to assess the efficacy. Methods: Eligibility criteria was defined as patients having histologically or cytologically proven lung cancer, no prior chemotherapy or one previous chemotherapy, an ECOG PS of 0–1, and adequate organ function. Amrubicin was administerd on day 1–3, as was CPT-11 on day 1,8, every 3 weeks. Results: A totall of 11 patients were registerd, consisted of 9 patients with small-cell lung cancer and two with non-small-cell lung cancer. Three patients were enrolled at the dose level 1 (amrubicin 40 mgm-2 and CPT-11 50 mgm-2), and all patients experienced dose-limiting toxicities (one grade 4 neutropenia that lasted for more than 4 days, three grade 3 febrile neutropenia(FN)). We set up the dose level (amrubicin 30 mgm-2 and CPT-11 60 mgm-2). Three out of 5 patients who were enrolled at this level developed one grade 3 FN and two more than grade 3 diarrhea. Subsequently, we reduced the dosage of CPT-11 (amrubicin 30 mgm-2 and CPT-11 50 mgm-2). One of three patients had grade 3 FN, and the others had grade 3 pneumonitis after second and third course, respectively. There were two partial responses with small-cell lung cancer. The pharmacokinetics studies indicate that there is no clear interaction between CPT-11 and amrubicin. Conclusions: We are not able to determine the MTD and RD. This study indicates that this combination is intolerable because of overlapping toxicities of both agents, and seems to be more ineffective than expected. No significant financial relationships to disclose.
Induction of Hamster Tumors of the Urinary Bladder by 3,2′-Dimethyl-4-Aminobiphenyl&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: B. T. So, E. L. Wynder
Journal: JNCI Journal of the National Cancer Institute (1972)

3,2′-Dimethyl-4-aminobiphenyl (3,2′-DMAB) was administered subcufaneously in doses of 100 mg/kg body weight to Syrian golden hamsters. Of 20 hamsters that lived over 158 days, 15 (12 females, 3 males) developed bladder tumors. In addition, 2 adenocarcinomas of the colon, 1 malignant lymphoma, 2 mammary carcinomas, 4 granulosa-theca cell tumors of the ovaries, and 1 squamous cell carcinoma of the skin were found. The mean cumulative doses and days required for the induction of bladder tumors were 2,400–2,700 mg/kg body weight (360–405 mg/animal) and 260–310 days. We believe this to be the first report of the induction of bladder tumors in Syrian golden hamsters by 3,2′;-DMAB.
Structural and functional evaluation of oxygenating keratin/silk fibroin scaffold and initial assessment of their potential for urethral tissue engineering
Authors: XiangGuo Lv, Zhe Li, ShiYan Chen, MinKai Xie, JianWen Huang, XuFeng Peng, RanXing Yang, HuaPing Wang, YueMin Xu, Chao Feng
Journal: Biomaterials (2016)
Prospective multicentric trial evaluating prognostic and predictive value of circulating tumor cells in first-line chemotherapy metastatic breast patients.
Authors: J. Pierga, T. D. Bachelot, F. Bidard, S. Delaloge, E. Brain, M. Campone, B. Asselain, C. Mathiot
Journal: Journal of Clinical Oncology (2010)

10544 Background: Detection of five or more circulating tumor cells (CTCs) per 7.5 ml in peripheral blood has been reported as an independent prognostic factor in metastatic breast cancer (MBC). A decrease in CTC during treatment could be associated with a better outcome (Cristofanilli, NEJM 2004). We conducted a multicentric prospective study to validate this marker in a large series of patients receiving specifically first line chemotherapy for MBC. Methods: CTC were measured in 7.5 ml of whole blood at baseline, before cycle 2, at clinical and/or radiological evaluation (C3-C4) and at tumor progression. Analysis was performed using the CellSearch System, combining EpCAM immunomagnetic selection (IMS) followed by anti-cytokeratin (A45B/B3) staining for CTC. Double labeling for HER2 was performed in a subgroup of patients. Results: From 06/07 to 9/09, 271 patients with measurable or evaluable disease were included in five French Cancer Centers. 261 were evaluable for CTC levels at baseline, before first cycle of chemotherapy. At baseline, median number of CTC was 2 (range 0-16 885). After one cycle of chemotherapy, median CTC number was 1 (range: 0-202). Incidence of CTC during treatment is shown in the Table. CTC HER2 status was assessed in 117 patients at baseline and was positive in 62% of the cases in at least one cell. Correlation with other clinical and biological parameters as serum marker (CA15.3) is ongoing. 18 months median follow-up will be reached in April 2010. Conclusions: We observed a clear decrease of CTC level after only one cycle of chemotherapy. These findings support the role of CTC enumeration as an adjunct to standard methods of monitoring disease status in MBC. However, about one-third of the patients with MBC had undetectable CTC level during first line treatment and even at tumor progression, suggesting a need for more sensitive methods of detection. Baseline C2 C3-C4 Progression ≥ 1 CTC 169 (65%) 77 (37%) 59 (28%) 20 (46%) ≥ 5 CTC 113 (43%) 38 (18%) 25 (12%) 13 (30%) Number of patients 261 209 210 43 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Veridex Veridex
Abstract 14706: Atorvastatin Would Prevent Chronic Kidney Injury in Patients With Chronic Heart Failure - A Prospective Randomized-Controlled Study -
Authors: Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Yusuke Iwasaki, Masato Kawasaki, Atsushi Kikuchi, Kentaro Ozu, Takumi Kondo, Kaoruko Sengoku, Hironori Yamomoto, Tsutomu Kawai, Satoshi Takahashi, Masashi Ishimi, Hideyuki Hakui, Masatake Fukunami
Journal: Circulation (2013)

Background: Chronic heart failure (CHF) and renal impairment frequently coexist. Statins have been evaluated for renoprotective effects in patients with coronary heart disease and dyslipidemia, and atorvastatin has been shown to improve renal function in those patients. However, there is little information available on the effect of atorvastatin on chronic kidney injury in CHF patients. Methods: We enrolled 38 mild to moderate CHF outpatients (NYHA class 1.9±0.6, ischemic origin: 54%) with left ventricular ejection fraction (LVEF) < 40% (28±8%) and serum creatinine < 3.0mg/dl. These patients were randomly assigned to receive atorvastatin (10mg/d) or conventional treatment for heart failure, and were prospectively followed up for at least three years. The measurement of serum creatinine level (sCr) was measured at entry, and repeated every at least 6 month after the entry, and chronic kidney injury (CKI) was defined as an increase of more than 0.3mg/dl in baseline sCr value. Furthermore, the circulating le...
Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomized trials.
Authors: Nobumasa Mizuno, Juan W. Valle, Junji Furuse, Mark Jitlal, Sandy Beare, Harpreet Wasan, John A. Bridgewater, Takuji Okusaka
Journal: Journal of Clinical Oncology (2013)

4120 Background: Two recent randomised studies (ABC-02 [UK] and BT22 [Japan]) have demonstrated the superiority of cisplatin and gemcitabine (CisGem) chemotherapy over gemcitabine (Gem) alone for patients with pathologically-proven advanced biliary tract cancer (BTC: cholangiocarcinoma, gallbladder and ampullary cancers). Methods: We performed a meta-analysis of individual patient-level data of these studies to establish the effect of CisGem vs. Gem on progression-free survival (PFS), overall survival (OS) and performed exploratory sub-group analyses. Results: A total of 493 patients, median age 64 years (range 23-84 years) with approximately equal sex distribution, were randomised (ABC-02 study n=410; BT22 study n=83) to receive either CisGem (n=245) or Gem (n=248). CisGem demonstrates a significant improvement in PFS (hazard ratio (HR)=0.64 (95%-CI: 0.53-0.76), p&lt;0.001) and OS (HR=0.65 (95%-CI: 0.54-0.78), p&lt;0.001) over Gem. This effect is most marked in patients with good performance status (PS 0-1): HR for PFS is 0.61 (95%-CI: 0.51-0.74), p&lt;0.001 and HR for OS is 0.64 (95%-CI: 0.53-0.77), p&lt;0.001. CisGem resulted in improved PFS and OS for intra- and extra-hepatic cholangiocarcinomas and gallbladder cancer. The treatment effect between UK and Japanese patients was consistent with respect to OS (HR=0.65, 95%-CI 0.53–0.79 and 0.65, 95%-CI 0.42–1.03, respectively); with similar median survival in the combination arms (median 11.7 and 11.1 months, respectively). Subgroups least likely to benefit included patients with ampullary tumours and poor performance score (PS2). Conclusions: CisGem is the standard of care for the first-line treatment of good-PS patients with advanced BTC regardless of ethnicity. Future studies should aim to enhance the effectiveness of this regimen in the first-line setting and establish the role of subsequent (second-line) therapy. Clinical trial information: ABC-02: NCT00262769, BT22; NCT00380588.
Application of serum proteomic patterns by ProteinChip SELDI system in diagnosis of gastric cancer
Authors: J. Lim, J. Cho, Y. Paik, Y. Chang, H. Kim
Journal: Journal of Clinical Oncology (2007)

10559 Background: Gastric cancer is one of the most common malignancy in the world and one of the leading causes of cancer related death in Korea. Most treatments for advanced gastric cancer have limited efficacy. So early detection of gastric cancer could have profound impact on the successful treatment. Application of multiple biomarkers may improve the diagnostic prediction to distinguish cancer from non-cancer. ProteinChip Surface-Enhanced Laser Desorption/Ionization Time-of-flight Mass Spectrometry (SELDI-TOF-MS) system is one of the currently used techniques to identify biomarkers for cancers. In this study, we have explored whether the serum proteomic patterns by ProteinChip SELDI system can differentiate gastric cancers from non-cancer cohorts. Methods: We have screened protein profiles of 100 serum samples obtained from 60 gastric cancer patients and 40 healthy individuals. Protein expression profiles were expressed on ProteinChip Array and analyzed by PreoteinChip Reader. Peak intensities were normalized by total ion currency and analyzed by the Biomarker Wizard Software to identify the peaks showing significantly different intensities between normal and cancer groups. Classification analysis and construction of decision trees were done with the Biomarker Pattern Software. Results: SELDI -TOF-MS by averaging 50 laser spots collected at a laser intensity setting of 160, a detector sensitivity of 6, and mean mass range of 30 kDa. Seventeen protein peaks shown significant differences between two groups were chosen to make a protein biomarker pattern. The decision tree which gives the highest discrimination included four peaks at 5,919, 8,583, 10,286, and 13,758 as splitters. The sensitivity and the specificity for classification of with the decision tree giving the highest discrimination were 96.7% (58/60) and 97.5% (39/40), respectively. When the protein biomarker pattern was tested with the blinded test set including 30 gastric cancer patients and 20 healthy individuals and, it yielded a sensitivity of 93.3% (28/30) and a specificity of 90% (18/20). Conclusions: These results suggest that serum-protein profiling pattern by SELDI system may distinguish gastric cancer patients from normal counterparts with relatively high sensitivity and specificity. No significant financial relationships to disclose.
Sentinel node mapping for esophageal cancer
Authors: H. Takeuchi, Y. Kitagawa, Y. Saikawa, A. Suto, M. Mukai, T. Nakahara, A. Kubo, M. Kitajima
Journal: Journal of Clinical Oncology (2007)

4552 Background: Extended radical esophagectomy with three-field lymph node dissection has been recognized as a standard procedure for esophageal cancer in Japan, even for clinically node negative cases. However, a significant increase of morbidity and mortality after the invasive procedure was reported in randomized trials. To eliminate the uniform application of highly invasive surgery, we hypothesized that sentinel node (SN) mapping plays a key role to obtain individual information and allows modification of the surgical procedure for early esophageal cancer. Methods: We have established radio-guided method to detect SNs in patient with early esophageal cancer using endoscopic injection of technetium-99m tin colloid. Preoperative lymphoscintigraphy and intra-operative use of hand held gamma probe were reliable to locate the radioactive SNs. Intra-operative gamma probing was also feasible in thoracoscopic or laparoscopic surgery using a special gamma detector which is introducible from trocar ports. Results: SN mapping has been performed for 105 patients with clinically N0 early esophageal cancer in our institute since 1999. Detection rate of hot node using our procedure was 93% (98/105). The mean number of sentinel nodes per case was 5.1. Thirty-three of 37 cases with lymph node metastasis showed positive sentinel nodes. The sensitivity to detect metastasis based on SN status was therefore 89% in our experience. Accuracy of metastatic status based on SN was 96% (94/98). SNs widely spread from cervical to abdominal areas. In more than 80% of the cases, at least one SN was located in the 2 nd or 3 rd compartment of regional lymph nodes. Conclusions: Our results suggest that SN concept for clinically N0 early esophageal cancer could be validated, and individualized selective and modified lymphadenectomy targeted on sentinel node basins for clinically N0 early esophageal cancer should become feasible and clinically useful as less invasive surgical procedures. No significant financial relationships to disclose.
Effects of Shugan-Liangxue prescription combined with anastrozole (ANA) on bone metabolism of ovariectomy (OVX) rats
Authors: P. Li, S. X. Liu
Journal: Journal of Clinical Oncology (2009)

e11551 Background: A randomized double-blind clinical trial has confirmed traditional Chinese medicine (TCM) Shugan-Liangxue prescription could relieve hot flashes in breast cancer with endocrine therapy. The purpose of this study was to observe the effects of TCM combined with ANA on serum estradiol (E 2 ) level and bone metabolism. Methods: The postmenopausal animal model was successful after OVX and testified by vaginal smear method. Sixty 6-month SD rats were randomly divided into control, TCM, ANA, ANA+TCM, alendronate sodium (AL), and sham groups. After 16 weeks intragastric administration, the bone mineral density (BMD) of femur and lumbar vertebra were measured by dual energy X-ray absorptiometry. The serum E 2 , osteocalcin (BGP), and prostaglandin E 2 (PGE 2 ) were detected by radioimmunoassay and pyridinoline (PYD) was by ELISA. Results: Serum E 2 level decreased in TCM, ANA, and ANA+TCM groups compared with the control (P&lt;0.05, P&lt;0.01, P&lt;0.001), BMD had no significant difference compared with the control. In ANA+TCM group, BGP (bone formation index) increased, PYD (bone absorption index) and PGE 2 declined significantly compared with ANA group (P&lt;0.05, P&lt;0.05, P&lt;0.01). PYD decreased greatly in TCM and AL groups compared with the control (P&lt;0.001, P&lt;0.001). Conclusions: TCM combined with ANA decreased serum E 2 level, but did not decline BMD of OVX rats. It could also elevate BGP and decrease PYD level in serum. It was possible that TCM combined with ANA could alleviate musculoskeletal pain through PGE 2 decrease. The effect of TCM reducing PYD was similar with AL. [Table: see text] No significant financial relationships to disclose.
P1299 : Platelet alpha-granule release in liver regeneration after hepatectomy
Authors: P. Starlinger, S. Haegele, D. Wanek, S. Zikeli, F. Offensperger, D. Schauer, E. Fleischmann, B. Gruenberger, C. Brostjan, T. Gruenberger, A. Assinger
Journal: Journal of Hepatology (2015)